Disclosure

EFPIA Disclosure

Nigaard is the Nordics based wholly owned subsidiary of Zambon S.p.A. headquartered in Italy. Zambon S.p.A. is an Italian pharmaceutical company. Zambon has been involved in the «Disclosure» project since 2015 with the aim of implementing the EFPIA Disclosure Code on Transfers of Value.
Specifically, the Disclosure Code requires that transfers of value between the pharmaceutical industry, healthcare professionals and healthcare organisations be published on a yearly basis, with reporting starting in 2016.
Nigaard Pharma AS was acquired by Zambon in July 2015. From the date of acquisition until December 2015 Nigaard did not carry out any activities relevant for EFPIA Disclosure as it was fully involved in the integration process in Zambon. For that reason publication of transfer of values of Nigaard will be effective starting from June 2017.

What are transfers of value?

Transfers of value are pecuniary benefits granted, such as:

  • Hospitality provided to a Healthcare Professional (HCP) for participating in a conference;
  • Compensation to Healthcare Professionals (HCP) and Healthcare Organisations (HCO) for a professional engagement based on the type of activity required;
  • Sponsorship of continuous medical education events

How can the full autonomy of Healthcare Professionals be ensured?

It is essential to maintain a continuous dialogue and discussion between pharmaceutical companies and Healthcare Professionals for the development of medicines and our collective wellbeing.

These relationships must be managed in a manner that the physicians can maintain their prescribing autonomy.
Disclosure of financial payments made to Healthcare Professionals and organisations will avoid any misunderstandings about physician autonomy.

Respect for privacy

Because the reporting of the transfer of value amounts received by individual Healthcare Professionals and Healthcare Organisations involves the publication of their personal information, Nigaard has left the decision entirely to the Healthcare Professional and Healthcare Organisation whether to authorise or deny the publication of transfers of value made to them.

Publication of values

This site contains a table that indicates the first and last name and address of the Healthcare Professional and the exact amount of the pecuniary benefits received only if the Healthcare Professional has authorised publication. The table also reports amounts of the pecuniary benefits to Healthcare Organisations only if the Healthcare Organisation has authorised publication.

If a Healthcare Professional or Healthcare Organisation denies publication, the transfer of value amounts made to them will be included in the aggregate value, in other words in the total amount of values paid by Nigaard.

Indirect transfers

It should be noted that not all transfers of value published on a named basis – upon authorisation of the Healthcare Professional – have been materially collected by the Healthcare Professional. The company has very often paid the corresponding amount indirectly and not to the Healthcare Professional, for example to an agency to cover the travel costs for the Healthcare Professional to attend an educational meeting deemed useful for their profession.

Nigaard extends their thanks

Nigaard extends its thanks to those Healthcare Professionals and Healthcare Organisations having authorised the publication of transfers of value on a named basis that occurred since 2016.

 

Finland

Disclosure TEMPLATE
Article 2 - Section 2.03
Full Name HCPs: City of Principal Practice HCOs: city where registered Country of Principal Practice Principal Practice Address Unique country local identifyer OPTIONAL Donations and Grants to HCOs (Art. 3.01.1.a) Contribution to costs of Events
(Art. 3.01.1.b & 3.01.2.a)
Fee for service and consultancy
(Art. 3.01.1.c & 3.01.2.c)
Transfers of Value re Research & Development as defined (Art. 3.04)        TOTAL OPTIONAL
(Art. 1.01) (Art. 3) (Schedule 1) (Art. 3) (Art. 3) Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event Registration Fees Travel & Accomodation Fees
CH
Related expenses agreed in the fee for service or consultancy contract
INDIVIDUAL HCPs INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2 6653 9412 2000 18065
Number of Recipients (named list, where appropriate) - Art. 3.2 8 12 1
% of total transfers of value to individual HCPs - Art. 3.2 100.00% 100.00% 100
CONTRIBUTIONS TO THE CONTINUING TRAINING OF HCP/HCO - for passive attendees at events lasting up to one day (according to Swiss Pharma Cooperation Code)
Aggregate amount attributable to transfers of value to such Recipients
Number of Recipients (named list, where appropriate)
% of total transfers of value to individual HCPs
HCOs INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)
 Suomen Neurologinen Yhdistys Turku Finland PL 52, 20521 Turku Finland 13500 13500
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2 Aggregate HCOs Aggregate HCOs Aggregate HCOs Aggregate HCOs Aggregate HCOs Aggregate HCOs
Number of Recipients (named list, where appropriate) - Art. 3.2 number number number number number number
% of total transfers of value to individual HCOs - Art. 3.2 % % % % % %
R&D AGGREGATE DISCLOSURE
Transfers of Value for Research & Development as defined - Article 3.04 and Schedule 1 CE OPTIONAL OPTIONAL OPTIONAL OPTIONAL OPTIONAL OPTIONAL TOTAL AMOUNT Not disclosed

2 June 2013

Norway

Disclosure TEMPLATE
Article 2 - Section 2.03
Full Name HCPs: City of Principal Practice HCOs: city where registered Country of Principal Practice Principal Practice Address Unique country local identifyer OPTIONAL Donations and Grants to HCOs (Art. 3.01.1.a) Contribution to costs of Events
(Art. 3.01.1.b & 3.01.2.a)
Fee for service and consultancy
(Art. 3.01.1.c & 3.01.2.c)
Transfers of Value re Research & Development as defined (Art. 3.04)        TOTAL OPTIONAL
(Art. 1.01) (Art. 3) (Schedule 1) (Art. 3) (Art. 3) Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event Registration Fees Travel & Accomodation Fees
CH
Related expenses agreed in the fee for service or consultancy contract
INDIVIDUAL HCPs INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2 15000 15000
Number of Recipients (named list, where appropriate) - Art. 3.2 3
% of total transfers of value to individual HCPs - Art. 3.2 100%
CONTRIBUTIONS TO THE CONTINUING TRAINING OF HCP/HCO - for passive attendees at events lasting up to one day (according to Swiss Pharma Cooperation Code)
Aggregate amount attributable to transfers of value to such Recipients
Number of Recipients (named list, where appropriate)
% of total transfers of value to individual HCPs
HCOs INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)
Normodis Oslo Norway Ombersveien 0 25000 25000
Normodis Oslo Norway Ombersveien 0 8500 8500
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2 Aggregate HCOs Aggregate HCOs Aggregate HCOs Aggregate HCOs Aggregate HCOs Aggregate HCOs
Number of Recipients (named list, where appropriate) - Art. 3.2 number number number number number number
% of total transfers of value to individual HCOs - Art. 3.2 % % % % % %
R&D AGGREGATE DISCLOSURE
Transfers of Value for Research & Development as defined - Article 3.04 and Schedule 1 CE OPTIONAL OPTIONAL OPTIONAL OPTIONAL OPTIONAL OPTIONAL TOTAL AMOUNT Not disclosed

2 June 2013

Sweden

Disclosure TEMPLATE
Article 2 - Section 2.03
Full Name HCPs: City of Principal Practice HCOs: city where registered Country of Principal Practice Principal Practice Address Unique country local identifyer OPTIONAL Donations and Grants to HCOs (Art. 3.01.1.a) Contribution to costs of Events
(Art. 3.01.1.b & 3.01.2.a)
Fee for service and consultancy
(Art. 3.01.1.c & 3.01.2.c)
Transfers of Value re Research & Development as defined (Art. 3.04)        TOTAL OPTIONAL
(Art. 1.01) (Art. 3) (Schedule 1) (Art. 3) (Art. 3) Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event Registration Fees Travel & Accomodation Fees
CH
Related expenses agreed in the fee for service or consultancy contract
INDIVIDUAL HCPs INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2 34000 34000
Number of Recipients (named list, where appropriate) - Art. 3.2 4
% of total transfers of value to individual HCPs - Art. 3.2 100%
CONTRIBUTIONS TO THE CONTINUING TRAINING OF HCP/HCO - for passive attendees at events lasting up to one day (according to Swiss Pharma Cooperation Code)
Aggregate amount attributable to transfers of value to such Recipients
Number of Recipients (named list, where appropriate)
% of total transfers of value to individual HCPs
HCOs INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)
Patientkraft, Svenska Parkinsonförb Stockholm Sweden Skeppargatan 52 105850 105850
Svenska Neurologfören Stockholm Sweden Karolinska sjukhuset 60000 60000
Svenska Parkinsonakademin Lund Sweden SUS, Lund 18000 18000
Barn och ungdomsmedicinska kliniken Jönköping Sweden Länssjukhuset Ryhov 5000 5000
Stockholm CF-center Stockholm Sweden Karolinska sjukhuset 4500 4500
SWEMODIS Stockholm Sweden Karolinska sjukhuset 41637 41637
Scandmodis Stockholm Sweden SUS, Lund 100000 100000
Neurologföreningen Stockholm Sweden Karolinska sjukhuset 75000 75000
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2 Aggregate HCOs Aggregate HCOs Aggregate HCOs Aggregate HCOs Aggregate HCOs Aggregate HCOs
Number of Recipients (named list, where appropriate) - Art. 3.2 number number number number number number
% of total transfers of value to individual HCOs - Art. 3.2 % % % % % %
R&D AGGREGATE DISCLOSURE
Transfers of Value for Research & Development as defined - Article 3.04 and Schedule 1 CE OPTIONAL OPTIONAL OPTIONAL OPTIONAL OPTIONAL OPTIONAL TOTAL AMOUNT Not disclosed

2 June 2013